US-based clinical diagnostic laboratory Personalis has entered a partnership with the Louisiana State University Health Sciences Center New Orleans Precision Medicine programme to provide comprehensive clinical genomic testing for tumour profiling and inherited genetic diseases.
Under the deal, Personalis will carry out clinical cancer testing and research services through its ACE CancerPlus test, which combines both DNA and RNA sequencing of more than 1,300 genes and uses the company’s ACE technology.
The testing will provide comprehensive tumour genomic profile data to guide therapy and ongoing research at the LSU Health New Orleans Precision Medicine programme.
Personalis chief scientific officer Dr Richard Chen said: "We are thrilled to work together with the LSU Health New Orleans Precision Medicine programme to provide our comprehensive, high accuracy genomic tests to their patients with cancer and genetic disorders.
"Working with LSU Health New Orleans, we want to provide the best possible care to patients by bringing genomics-based precision medicine to the bedside.
"Not only will this partnership bring benefits to patients, but it will also bring the substantial medical and scientific expertise at the two institutions together in a research capacity that will benefit future patients."
In addition, the company will provide its ACE Clinical Exome test for the diagnosis of genetic disorders in paediatric and adult patients.
The ACE Clinical Exome Test targets essentially all human genes using the company’s ACE exome technology.
Personalis provides advanced genome sequencing and interpretation services to clinicians and researchers for cancer and inherited genetic diseases.